Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:DXCMNASDAQ:PODD On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeDXCMDexCom$86.67+1.1%$76.38$57.52▼$118.80$33.98B1.464.34 million shs2.42 million shsPODDInsulet$311.77-1.7%$282.34$173.00▼$329.33$21.94B1.37707,804 shs682,612 shsThe 10 Best AI Stocks to Own in 2025Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceDXCMDexCom+1.08%+0.83%+3.98%+11.34%-26.60%PODDInsulet-1.70%-3.92%+18.09%+23.81%+66.12%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationDXCMDexCom4.831 of 5 stars3.54.00.04.73.52.51.9PODDInsulet4.1331 of 5 stars2.43.00.04.93.30.81.9Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceDXCMDexCom 2.95Moderate Buy$98.3213.44% UpsidePODDInsulet 2.82Moderate Buy$318.412.13% UpsideCurrent Analyst Ratings BreakdownLatest PODD and DXCM Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/30/2025DXCMDexComThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$104.005/30/2025PODDInsuletThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$380.005/27/2025PODDInsuletRaymond JamesSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$328.00 ➝ $360.005/22/2025DXCMDexComCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$82.00 ➝ $102.005/22/2025PODDInsuletCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$320.00 ➝ $380.005/16/2025PODDInsuletSanford C. BernsteinSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform5/13/2025PODDInsuletWolfe ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradePeer Perform ➝ Outperform$350.005/9/2025PODDInsuletOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$312.00 ➝ $324.005/5/2025DXCMDexComBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetEqual Weight ➝ Equal Weight$90.00 ➝ $93.005/2/2025DXCMDexComPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$100.00 ➝ $90.005/2/2025DXCMDexComCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$103.00 ➝ $106.00(Data available from 6/7/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookDXCMDexCom$4.15B8.19$2.18 per share39.75$5.38 per share16.11PODDInsulet$2.20B9.98$4.10 per share75.96$10.49 per share29.72Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateDXCMDexCom$576.20M$1.3460.6135.232.3014.29%30.14%10.11%7/24/2025 (Estimated)PODDInsulet$206.30M$5.5653.8562.733.6220.19%24.46%8.33%8/6/2025 (Estimated)Latest PODD and DXCM EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/8/2025Q1 2025PODDInsulet$0.81$1.02+$0.21$0.50$543.20 million$569.00 million5/1/2025Q1 2025DXCMDexCom$0.33$0.32-$0.01$0.27$1.02 billion$1.04 billionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthDXCMDexComN/AN/AN/AN/AN/APODDInsuletN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioDXCMDexCom0.591.471.28PODDInsulet1.213.682.80Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipDXCMDexCom97.75%PODDInsuletN/AInsider OwnershipCompanyInsider OwnershipDXCMDexCom0.32%PODDInsulet0.39%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableDXCMDexCom7,600392.11 million389.60 millionOptionablePODDInsulet2,60070.38 million69.82 millionOptionablePODD and DXCM HeadlinesRecent News About These CompaniesQ1 Patient Monitoring Earnings: Insulet (NASDAQ:PODD) Earns Top MarksJune 6 at 5:23 AM | msn.comTD Cowen Raises Insulet (PODD) Price Target, Maintains Buy RatingJune 5 at 1:17 PM | insidermonkey.comUpdate: Insulet Corp.’s Trade Secrets Jury Award Reduced From $452 Million to $59.4 Million to Avoid Double RecoveryJune 4 at 5:11 PM | jdsupra.comHere's Why Insulet (PODD) is a Strong Growth StockJune 4 at 10:51 AM | zacks.comContravisory Investment Management Inc. Increases Holdings in Insulet Co. (NASDAQ:PODD)June 4 at 6:33 AM | marketbeat.comCzech National Bank Boosts Holdings in Insulet Co. (NASDAQ:PODD)June 4 at 4:56 AM | marketbeat.comInsulet Co. (NASDAQ:PODD) Shares Purchased by Rhumbline AdvisersJune 4 at 4:55 AM | marketbeat.comS&P 500 Wraps Up Best May Since 1990: 5 Top Stocks in the ETFJune 3, 2025 | zacks.comReflecting On Patient Monitoring Stocks’ Q1 Earnings: Masimo (NASDAQ:MASI)June 3, 2025 | msn.comAEGON ASSET MANAGEMENT UK Plc Lowers Stake in Insulet Co. (NASDAQ:PODD)June 3, 2025 | marketbeat.com1 Surging Stock with Exciting Potential and 2 to QuestionJune 2, 2025 | finance.yahoo.comGoldman Sachs Bullish On Dexcom And Insulet As Diabetes Tech SurgesJune 2, 2025 | benzinga.comThe Goldman Sachs Group Initiates Coverage on Insulet (NASDAQ:PODD)June 1, 2025 | americanbankingnews.comGoldman Sachs Initiates Coverage of Insulet (PODD) with Buy RatingMay 31, 2025 | insidermonkey.comInsulet (NASDAQ:PODD) Earns Buy Rating from Analysts at The Goldman Sachs GroupMay 31, 2025 | marketbeat.comGAMMA Investing LLC Has $1.74 Billion Stock Position in Insulet Co. (NASDAQ:PODD)May 31, 2025 | marketbeat.comCalifornia State Teachers Retirement System Decreases Holdings in Insulet Co. (NASDAQ:PODD)May 31, 2025 | marketbeat.comGoldman Sachs Initiates Coverage of Insulet (PODD) with Buy RecommendationMay 31, 2025 | msn.comInsulet (NASDAQ:PODD) Rating Increased to Buy at Wall Street ZenMay 31, 2025 | americanbankingnews.comInsulet (NASDAQ:PODD) Upgraded by Wall Street Zen to "Buy" RatingMay 31, 2025 | marketbeat.comGoldman Sachs initiates coverage of medtech stocks Insulet and Dexcom at BuyMay 30, 2025 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All Headlines3 Defense Stocks That Will Profit From a Golden DomeBy Chris Markoch | May 30, 2025View 3 Defense Stocks That Will Profit From a Golden DomeBullish NVIDIA Market Set to Surge 50% Ahead of Q1 EarningsBy Thomas Hughes | May 27, 2025View Bullish NVIDIA Market Set to Surge 50% Ahead of Q1 EarningsIntel’s Turnaround May Be the Best Bet No One’s WatchingBy Jeffrey Neal Johnson | May 30, 2025View Intel’s Turnaround May Be the Best Bet No One’s WatchingAnalysts Think These Stocks Could More Than Double in ValueBy Nathan Reiff | May 23, 2025View Analysts Think These Stocks Could More Than Double in ValueInsulet Surges on Q1 Beat, Emerges as a Top S&P 500 PerformerBy Jeffrey Neal Johnson | May 14, 2025View Insulet Surges on Q1 Beat, Emerges as a Top S&P 500 PerformerPODD and DXCM Company DescriptionsDexCom NASDAQ:DXCM$86.67 +0.93 (+1.08%) Closing price 06/6/2025 04:00 PM EasternExtended Trading$86.82 +0.16 (+0.18%) As of 06/6/2025 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions. It has also submitted FDA review for Dexcom Stelo for people with type 2 diabetes. The company has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. It markets its products directly to endocrinologists, physicians, and diabetes educators. The company was incorporated in 1999 and is headquartered in San Diego, California.Insulet NASDAQ:PODD$311.77 -5.39 (-1.70%) Closing price 06/6/2025 04:00 PM EasternExtended Trading$316.34 +4.57 (+1.47%) As of 06/6/2025 06:14 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours. The company sells its products primarily through independent distributors and pharmacy channels, as well as directly in the United States, Canada, Europe, the Middle East, Australia, and internationally. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 06/02 - 06/06 This Banking Giant Just Got a $90 Price Target Upgrade Broadcom Slides on Solid Earnings, AI Outlook Still Strong The Market’s Silent Warning: What Bonds and Gold Reveal MongoDB Affirms Outlook and Accelerates Stock Price Reversal Are NVIDIA's Ethernet Wins Signs of Hope or Horror for Arista? AT&T: Is This Telecom Giant a Buy or a Bye for Your Portfolio? Why Visa's Innovation Engine Keeps It a Top Portfolio Pick Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
